Bristol Myers Squibb Surpasses Market Returns: Facts Worth Knowing

Bristol Myers Squibb (BMY) closed at $47.66, a +1.32% move from the previous day, outpacing the S&P 500's 0.61% gain. The biopharmaceutical company's stock has fallen by 5.86% in the past month, lagging the Medical sector's loss of 0.67% and the S&P 500's gain of 3.85%. Analysts expect an EPS of $1.53 and net sales of $11.32 billion in its upcoming earnings disclosure. The Zacks Consensus Estimates predict earnings of $6.76 per share and a revenue of $46.3 billion for the entire fiscal year.

Bristol Myers Squibb (BMY) closed at $47.66 on July 2, 2025, marking a +1.32% increase from the previous day's close, outpacing the S&P 500's 0.61% gain. This performance comes after a month of underwhelming returns, with BMY's stock falling by 5.86% compared to a 0.67% loss in the Medical sector and a 3.85% gain in the S&P 500 [2].

Analysts are closely monitoring the company's upcoming earnings disclosure, set for July 31, 2025. The consensus estimates project an EPS of $1.53 and net sales of $11.32 billion, marking a significant drop compared to the same period last year [2]. For the entire fiscal year, the Zacks Consensus Estimates predict earnings of $6.76 per share and a revenue of $46.3 billion, indicating substantial year-over-year changes of +487.83% and -4.13%, respectively [2].

The company's valuation metrics also warrant attention. As of the latest data, BMY holds a Forward P/E ratio of 6.96, which is lower than the industry average of 19.46. Additionally, the PEG ratio stands at 1.39, indicating a favorable valuation compared to its peers [2].

Recent analyst revisions and changes in the Zacks Rank provide further insights. The Zacks Rank currently stands at #3 (Hold), suggesting a cautious stance on the stock. Analysts have made several recent changes, including upgrades and downgrades, reflecting the latest business trends and short-term outlook [1].

In conclusion, Bristol Myers Squibb's recent performance highlights the importance of closely monitoring earnings reports and analyst revisions. Investors should stay informed about the company's financial health and the broader market trends affecting its sector.

References:
[1] https://finance.yahoo.com/quote/BMY/analysis/
[2] https://www.nasdaq.com/articles/bristol-myers-squibb-bmy-surpasses-market-returns-some-facts-worth-knowing-0